A pilot study of a response oriented chemotherapeutic regimen combined with autologous peripheral blood progenitor cell transplantation in aggressivenon-Hodgkin's lymphoma

Fourteen consecutive patients with poor-risk aggressive NHL who at presenta tion had any one of four risk factors underwent response oriented induction chemotherapy and successive high-dose chemotherapy followed by autologous PBPC transplantation. After treatment with three cycles of conventional CHO P with G-CSF support (CHOP-G), the response was evaluated. For patients who achieved a complete remission (CR), an additional three cycles of CHOP-G w ere administered, while for partial response patients, another induction re gimen including some non-cross-resistant agents was given; three cycles of VIPDexa-G (etoposide, ifosfamide, cisplatinum and dexamethasone) +/- two cy cles of ENAP-G (mitoxantrone, etoposide, cytosine arabinoside and prednison e), were given. The scheduled induction chemotherapy, was followed by treat ment with a high-dose cytoreductive regimen followed by autologous PBPC tra nsplantation. After three cycles of CHOP-C, four patients (29%) achieved a CR, and 10 (71 %) achieved a partial response (PR), When all scheduled induction therapy w as completed, 10 patients (71%) had a CR. All 14 patients received high-dos e therapy and obtained a complete hematologic recovery, except for one with a bone marrow relapse two months after transplantation. Evaluation of resp onse after high-dose therapy showed 12 CRs (86%) which included three addit ional CRs, one PR, and one toxicity-related death. With a median follow-up of 12 months (range, 4 to 40), 12 are alive, with 11 in continuous first CR , and one relapse. The 2-year overall survival (OS) rate and event-free sur vival (EFS) rate are 77% and 79%, respectively, while the disease-free surv ival (DFS) rate is 92%. In conclusion, this pilot study suggests that respo nse oriented induction chemotherapy and successive high-dose chemotherapy f ollowed by autologous PBPC transplantation is commendable and can be associ ated with a high rate of remission and DFS for poor risk subjects with aggr essive NHL.